Manila Times Business
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company’s other platformsNew data from Part 1 of the J&J sponsored Phase 2 CONVERGE study, evaluating JNJ-1900 (NBTXR3) for patients with Stage 3 inoperable non-small cell lung cancer (NSCLC), presented at the 2026 annual European Society for Radiotherapy and Oncology (ESTRO)Announced FDA acceptance of a protocol amendm
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Keystone Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering
2h ago
Moderna Launches Moderna Direct with "eCommerce Powered by FFF Enterprises™”
2h ago
ATN International, Inc. Completes Initial Closing on the Sale of its Towers and Updates 2026 Outlook
2h ago
Neuronetics Appoints Robert Greene as Senior Vice President Sales
2h ago